Davis M E, Conger A D, Sodicoff M
Int J Radiat Oncol Biol Phys. 1987 Apr;13(4):575-8. doi: 10.1016/0360-3016(87)90074-5.
On day 14 post-conception, near the end of the period of major organogenesis, pregnant rats were injected intravenously or intraperitoneally with WR 2721 spiked with 14C-WR 2721. The radioprotectant was shown to cross the placenta rapidly when administered by either route, and the concentration of WR 2721 in the embryos, placentae, and maternal blood plasma was determined during the period 5 to 90 minutes following administration. The concentration of WR 2721 increased continuously in the embryos during this period and did so against a decreasing concentration in the maternal blood. Injection of WR 2721 at 100 mg/kg of maternal body weight resulted in the presence of 8-9-mg/kg embryo weight; this embryo level is about 1/2 the injected dose of WR 2721 currently being used in human radiotherapy trials, that is, 20 mg/kg (740 mg/m2) body weight. Previous toxicity studies of 9, 11, and 14 day rat embryos have shown that this 100 mg/kg dose is much below the level which produces embryotoxic effects.
在受精后第14天，接近主要器官发生期结束时，给怀孕大鼠静脉内或腹腔内注射掺入了14C-WR 2721的WR 2721。结果表明，无论通过哪种途径给药，这种辐射防护剂都能迅速穿过胎盘，并且在给药后5至90分钟内测定胚胎、胎盘和母体血浆中WR 2721的浓度。在此期间，胚胎中WR 2721的浓度持续增加，而母体血液中的浓度则在下降。以100 mg/kg母体体重注射WR 2721后，胚胎中的含量为8 - 9 mg/kg胚胎体重；这个胚胎水平约为目前人类放射治疗试验中所用WR 2721注射剂量的1/2，即20 mg/kg（740 mg/m2）体重。先前对9、11和14天龄大鼠胚胎的毒性研究表明，这种100 mg/kg的剂量远低于产生胚胎毒性作用的水平。
